drugset / Trial / NCT06619522
A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis
NaSingle-groupOpen-labelTreatment
Summary
To assess INCB05643 + ruxolitinib JAKi-naive patients with myelofibrosis
Timeline
- Start
- 2024-09-11
- Primary completion
- 2025-05-09
- Completion
- 2025-05-09
Outcome
Outcome not reported
Stopped (Enrollment): “0 participant accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB57643 | Unknown | — | Oral |
| Subject | Ruxolitinib | Small molecule | — | Oral |